These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33328556)

  • 1. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
    Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
    Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 3. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P; Foglizzo V; Harada G; Repetto M; Kulick A; de Stanchina E; de Marchena M; Auwardt S; Sayed Ahmed S; Bremer NV; Yang SR; Feng Y; Zhou C; Kong N; Liang R; Xu H; Zhang B; Bardelli A; Toska E; Ventura A; Drilon A; Cocco E
    Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
    Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF; Demetri GD
    Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 7. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E; Scaltriti M; Drilon A
    Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Larotrectinib in NTRK-Rearranged Solid Tumors
    Wilson FH; Herbst RS
    Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y; Matsumoto M; Takano N; Hirao M; Matsuda K; Tozuka T; Onda N; Nakamichi S; Takeuchi S; Miyanaga A; Noro R; Gemma A; Seike M
    Cancer Med; 2024 Jun; 13(12):e7393. PubMed ID: 38923428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
    Cocco E; Lee JE; Kannan S; Schram AM; Won HH; Shifman S; Kulick A; Baldino L; Toska E; Arruabarrena-Aristorena A; Kittane S; Wu F; Cai Y; Arena S; Mussolin B; Kannan R; Vasan N; Gorelick AN; Berger MF; Novoplansky O; Jagadeeshan S; Liao Y; Rix U; Misale S; Taylor BS; Bardelli A; Hechtman JF; Hyman DM; Elkabets M; de Stanchina E; Verma CS; Ventura A; Drilon A; Scaltriti M
    Cancer Discov; 2021 Jan; 11(1):126-141. PubMed ID: 33004339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolo[1,5-
    Mahajan AT; Shivani ; Datusalia AK; Coluccini C; Coghi P; Chaudhary S
    Molecules; 2024 Jul; 29(15):. PubMed ID: 39124968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
    Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
    J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
    Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRK Inhibitors: Clinical Development of Larotrectinib.
    Bhangoo MS; Sigal D
    Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.
    Zhuo LS; Wang MS; Wu FX; Xu HC; Gong Y; Yu ZC; Tian YG; Pang C; Hao GF; Huang W; Yang GF
    J Med Chem; 2021 Oct; 64(20):15503-15514. PubMed ID: 34668694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
    Drilon A; Nagasubramanian R; Blake JF; Ku N; Tuch BB; Ebata K; Smith S; Lauriault V; Kolakowski GR; Brandhuber BJ; Larsen PD; Bouhana KS; Winski SL; Hamor R; Wu WI; Parker A; Morales TH; Sullivan FX; DeWolf WE; Wollenberg LA; Gordon PR; Douglas-Lindsay DN; Scaltriti M; Benayed R; Raj S; Hanusch B; Schram AM; Jonsson P; Berger MF; Hechtman JF; Taylor BS; Andrews S; Rothenberg SM; Hyman DM
    Cancer Discov; 2017 Sep; 7(9):963-972. PubMed ID: 28578312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.